JTK 652Alternative Names: JTK-652
Latest Information Update: 29 Apr 2009
At a glance
- Originator Japan Tobacco
- Class Antivirals
- Mechanism of Action Virus internalisation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 26 Apr 2009 Final adverse events and efficacy data from a phase I trial in HCV infections presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL-2009)
- 30 Jun 2008 Discontinued - Phase-I for Hepatitis C (PO)
- 31 Oct 2007 Phase-I clinical trials in Hepatitis C treatment (PO)